Vera Therapeutics Files 8-K on Financials
Ticker: VERA · Form: 8-K · Filed: Mar 20, 2024 · CIK: 1831828
| Field | Detail |
|---|---|
| Company | Vera Therapeutics, INC. (VERA) |
| Form Type | 8-K |
| Filed Date | Mar 20, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, operations
TL;DR
Vera Therapeutics dropped an 8-K detailing its financial condition and operations.
AI Summary
Vera Therapeutics, Inc. filed an 8-K on March 20, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing provides an update on the company's financial status and operational performance.
Why It Matters
This filing provides investors with crucial updates on Vera Therapeutics' financial health and operational performance, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Vera Therapeutics, Inc. (company) — Registrant
- March 20, 2024 (date) — Date of Report
- 8000 Marina Boulevard, Suite 120 (address) — Principal Executive Offices
- Brisbane, California (location) — Principal Executive Offices Location
- 94005 (zip_code) — Principal Executive Offices Zip Code
- 650-770-0077 (phone_number) — Registrant's telephone number
FAQ
What specific financial information is being reported in this 8-K?
The 8-K reports on Vera Therapeutics, Inc.'s 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K filing submitted?
The filing was submitted on March 20, 2024.
What is Vera Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 8000 Marina Boulevard, Suite 120, Brisbane, California, 94005.
What is the company's telephone number?
The registrant's telephone number is (650) 770-0077.
What is the Standard Industrial Classification (SIC) code for Vera Therapeutics, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 527 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-03-20 07:30:10
Key Financial Figures
- $0.001 — hich registered Class A common stock, $0.001 par value per share VERA The Nasdaq
Filing Documents
- vera-20240320.htm (8-K) — 46KB
- vera-ex99_1.htm (EX-99.1) — 104KB
- img47757703_0.jpg (GRAPHIC) — 9KB
- 0000950170-24-033947.txt ( ) — 288KB
- vera-20240320.xsd (EX-101.SCH) — 26KB
- vera-20240320_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On March 20, 2024, Vera Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023, and providing recent corporate updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. All of the information furnished in this Item 2.02 and Item 9.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of Vera Therapeutics, Inc., dated March 20, 2024 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Vera Therapeutics, Inc. Date: March 20, 2024 By: /s/ Sean Grant Sean Grant, Chief Financial Officer